Related Experiment Videos

Novel effects of macrolide antibiotics on cardiovascular diseases

Jun-ichi Suzuki1, Masahito Ogawa, Keiichi Hishikari

  • 1Department of Advanced Clinical Science and Therapeutics, University of Tokyo, Tokyo, Japan. junichisuzuki-circ@umin.ac.jp

Cardiovascular Therapeutics
|December 6, 2011
PubMed

Insights

Macrolide antibiotics, like clarithromycin, show potential in preventing cardiovascular diseases by suppressing matrix metalloproteinases (MMPs). This review explores MMP roles in heart conditions and macrolide effects on tissue remodeling.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Immunology

Background:

  • Macrolide antibiotics are widely used for infections but possess immunomodulatory effects.
  • Matrix metalloproteinases (MMPs) play a role in cardiovascular diseases, with their activity often upregulated.
  • The impact of macrolides on cardiovascular health remains incompletely understood due to conflicting clinical data.

Purpose of the Study:

  • To review the established roles of MMPs in various cardiovascular diseases.
  • To explore the potential of macrolides in preventing adverse tissue remodeling in cardiovascular conditions.
  • To summarize existing research on macrolide effects on cardiovascular diseases.

Main Methods:

  • Literature review of studies investigating MMPs in cardiovascular diseases.
  • Analysis of research on macrolide antibiotics, including clarithromycin, and their biological effects.
  • Examination of animal model data demonstrating clarithromycin's protective effects.

Main Results:

  • MMP activity is significantly implicated in the pathogenesis of myocarditis, cardiac transplant rejection, and myocardial infarction.
  • Clarithromycin demonstrated efficacy in suppressing the development of myocarditis, cardiac rejection, and myocardial ischemia in preclinical models.
  • Macrolides exhibit anti-inflammatory properties and can modulate MMP activity.

Conclusions:

  • Macrolides, particularly clarithromycin, may offer a therapeutic strategy for mitigating adverse tissue remodeling in cardiovascular diseases.
  • Targeting MMPs with macrolides presents a promising avenue for cardiovascular disease prevention.
  • Further clinical investigation is warranted to confirm the cardiovascular benefits of macrolides.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...